Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): A multicentre, randomised, double-blind study
Landewé R et al. Lancet 2018. doi: 10.1016/S0140-6736(18)31362-X
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.